AI Article Synopsis

  • Recurrent ovarian cancer patients, especially those resistant to platinum treatments, currently have few effective curative options, prompting a phase 2 clinical trial (NCT02853318) that combined pembrolizumab with bevacizumab and oral cyclophosphamide.
  • The trial included 40 patients and showed promising results, with a median progression-free survival of 10.2 months, a 47.5% objective response rate, and 30% of patients achieving stable disease for over a year while maintaining a good quality of life.
  • Comprehensive analysis revealed that increased T and B cell count and specific microbiome patterns correlated with strong clinical responses, suggesting that understanding the immune environment and gut microbiome could enhance future cancer treatment

Article Abstract

Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase T cell infiltration into the tumor, and oral cyclophosphamide, to reduce the number of regulatory T cells. The trial accrued 40 heavily pretreated recurrent ovarian cancer patients. The primary endpoint, progression free survival, was extended to a median of 10.2 months. The secondary endpoints demonstrated an objective response rate of 47.5%, and disease control in 30% of patients for over a year while maintaining a good quality of life. We performed comprehensive molecular, immune, microbiome, and metabolic profiling on samples of trial patients. Here, we show increased T and B cell clusters and distinct microbial patterns with amino acid and lipid metabolism are linked to exceptional clinical responses. This study suggests the immune milieu and host-microbiome can be leveraged to improve antitumor response in future immunotherapy trials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621351PMC
http://dx.doi.org/10.1038/s41467-024-54565-8DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
12
recurrent ovarian
8
cancer patients
8
integrative multi-omics
4
multi-omics analysis
4
analysis uncovers
4
uncovers tumor-immune-gut
4
tumor-immune-gut axis
4
axis influencing
4
influencing immunotherapy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!